Efficient Gene Editing in Primary Human T Cells

Couzin-Frankel, 2013, Breakthrough of the year 2013. Cancer immunotherapy, Science, 342, 1432, 10.1126/science.342.6165.1432

Corrigan-Curay, 2014, T-cell immunotherapy: looking forward, Mol. Ther., 342, 1564, 10.1038/mt.2014.148

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222

Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001

Didigu, 2014, Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection, Blood, 123, 61, 10.1182/blood-2013-08-521229

Barrett, 2015, Chimeric antigen receptor- and TCR-modified T cells enter Main street and Wall street, J. Immunol., 195, 755, 10.4049/jimmunol.1500751

Jensen, 2015, Designing chimeric antigen receptors to effectively and safely target tumors, Curr. Opin. Immunol., 33, 9, 10.1016/j.coi.2015.01.002

Schumann, 2015, Generation of knock-in primary human T cells using Cas9 ribonucleoproteins, Proc. Natl. Acad. Sci. U.S.A., 112, 10437, 10.1073/pnas.1512503112

Hendel, 2015, Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells, Nat. Biotechnol., 33, 985, 10.1038/nbt.3290

Poirot, 2015, Multiplex genome edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies, Cancer Res., 75, 3853, 10.1158/0008-5472.CAN-14-3321